Skip to main content

Table 1 Biochemical parameters

From: Oral treatment with a zinc complex of acetylsalicylic acid prevents diabetic cardiomyopathy in a rat model of type-2 diabetes: activation of the Akt pathway

Parameters

ZL

(n = 5–9)

ZDF

(n = 7)

ZDF + Zn(ASA)2

(n = 5–6)

ZL + Zn(ASA)2

(n = 6–10)

Plasma glucose (mmol/L)

11.8 ± 0.7

49.4 ± 2.8*$

39.0 ± 3.6*#$

11.4 ± 0.7

Plasma HDL cholesterol (mmol/L)

0.27 ± 0.01

1.96 ± 0.11*$

1.83 ± 0.06*$

0.28 ± 0.02

Plasma total cholesterol (mmol/L)

2.56 ± 0.13

8.68 ± 0.89*$

9.27 ± 0.95*$

2.24 ± 0.14

Plasma triglycerides (mmol/L)

1.0 ± 0.2

13.5 ± 1.1*$

17.4 ± 1.3*#$

1.1 ± 0.1

Non-esterified fatty acid (mmol/L)

0.21 ± 0.04

0.45 ± 0.07*$

0.49 ± 0.09*$

0.22 ± 0.01

Serum insulin (μg/L)

0.75 ± 0.10

0.71 ± 0.08

0.70 ± 0.09

1.33 ± 0.25

Plasma GOT/AST (U/L)

64 ± 4

77 ± 12

107 ± 26

81 ± 4

  1. Biochemical profile of ZDF (Zucker diabetic fatty) and Zucker Lean (nondiabetic) rats after 24 days of treatment with either vehicle or zinc complex of acetylsalicylic acid (Zn(ASA)2). Values are mean ± SEM. * P < 0.05 vs ZL, # P < 0.05 vs ZDF, $ P < 0.05 vs ZL + Zn(ASA)2
  2. GPT indicates glutamate–oxaloacetate transaminase, AST aspartate aminotransferase, n number of animals analysed